Meeting
2013 ASCO Annual Meeting
A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL).
Authors
Michael Wang
The University of Texas MD Anderson Cancer Center, Houston, TX
Michael Wang , Leo I. Gordon , Simon Rule , Andre Goy , Olivier Hermine , Aleksandra Rizo , Sen Hong Zhuang , Martin H. Dreyling
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01776840
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS8613^)
DOI
10.1200/jco.2013.31.15_suppl.tps8613
Abstract #
TPS8613^
Poster Bd #
57B
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL).
First Author: Martin H. Dreyling
Poster
2017 ASCO Annual Meeting
Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL).
First Author: Charalambos Andreadis
Poster
2015 ASCO Annual Meeting
A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
First Author: Nathan Hale Fowler
Poster
2014 ASCO Annual Meeting
A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
First Author: Nathan Hale Fowler